Literature DB >> 28982876

Radical Cystectomy Versus Chemoradiation for Muscle-invasive Bladder Cancer: Impact of Treatment Facility and Sociodemographics.

Waqar Haque1, Vivek Verma2, E Brian Butler3, Bin S Teh4.   

Abstract

BACKGROUND: The present study sought to compare the differences in practice patterns, as well as clinical outcomes for patients with muscle-invasive bladder cancer undergoing treatment with either radical cystectomy (RC) or concurrent chemoradiaiton (CRT). PATIENTS AND METHODS: The National Cancer Data Base (NCDB) was queried for patients diagnosed with T2/T3/T4aN0M0 bladder cancer, between 2004-2013, that received definitive treatment with either RC or CRT.
RESULTS: 16,960 patients met the inclusion criteria; 1,450 (8.5%) underwent CRT, while 15,510 (91.5%) were treated with RC. Patients undergoing CRT were older, more likely to be female, African American, received treatment at an academic facility, and lived <20 miles of the treatment facility. CRT was associated with worse median OS (32.8 months vs. 36.1 months; p=0.0004).
CONCLUSION: Older patients are more likely to undergo bladder preservation therapy, while those living farther away from treatment facilities are less likely to under CRT. Copyright
© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Bladder cancer; bladder preservation; chemoradiation; chemotherapy; cystectomy; radiation therapy

Mesh:

Year:  2017        PMID: 28982876     DOI: 10.21873/anticanres.11994

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  11 in total

1.  The perils of using registry data to compare the survival and cost of radical cystectomy and trimodality therapy in bladder cancer.

Authors:  Abhishek A Solanki; Stanley L Liauw
Journal:  Transl Androl Urol       Date:  2019-12

2.  Addition of chemotherapy to hypofractionated radiotherapy for glioblastoma: practice patterns, outcomes, and predictors of survival.

Authors:  Waqar Haque; Vivek Verma; E Brian Butler; Bin S Teh
Journal:  J Neurooncol       Date:  2017-10-31       Impact factor: 4.130

3.  Long-term outcomes by response to neoadjuvant chemotherapy or chemoradiation in patients with resected pancreatic adenocarcinoma.

Authors:  Ahmed Khattab; Sunita Patruni; Stephen Abel; Shaakir Hasan; Ethan B Ludmir; Gene Finley; Dulabh Monga; Rodney E Wegner; Vivek Verma
Journal:  J Gastrointest Oncol       Date:  2019-10

4.  National Cancer Database report of nonmetastatic esophageal small cell carcinoma.

Authors:  Vivek Verma; Richard L Sleightholm; Penny Fang; Jeffrey M Ryckman; Chi Lin
Journal:  Cancer Med       Date:  2018-11-06       Impact factor: 4.452

5.  Utilization of intensity modulated radiation therapy for anal cancer in the United States.

Authors:  Waqar Haque; Vivek Verma; E Brian Butler; Bin S Teh
Journal:  J Gastrointest Oncol       Date:  2018-06

6.  Chemoradiotherapy versus chemotherapy alone for unresected intrahepatic cholangiocarcinoma: practice patterns and outcomes from the national cancer data base.

Authors:  Vivek Verma; Adams Kusi Appiah; Tim Lautenschlaeger; Sebastian Adeberg; Charles B Simone; Chi Lin
Journal:  J Gastrointest Oncol       Date:  2018-06

7.  Survival and Characteristics of Bladder Cancer: Analysis of the Malaysian National Cancer Registry.

Authors:  Mohd Nasrullah Nik Ab Kadir; Suhaily Mohd Hairon; Najib Majdi Yaacob; Azizah Ab Manan; Nabihah Ali
Journal:  Int J Environ Res Public Health       Date:  2021-05-14       Impact factor: 3.390

8.  Clinical benefit to regionalization of care for muscle invasive bladder cancer.

Authors:  Waqar Haque; E Brian Butler; Bin S Teh
Journal:  Transl Androl Urol       Date:  2018-03

9.  National Cancer Database Comparison of Radical Cystectomy vs Chemoradiotherapy for Muscle-Invasive Bladder Cancer: Implications of Using Clinical vs Pathologic Staging.

Authors:  Hong-Yiou Lin; Hong Ye; Kenneth M Kernen; Jason M Hafron; Daniel J Krauss
Journal:  Cancer Med       Date:  2018-10-10       Impact factor: 4.452

10.  TOP2A and CENPF are synergistic master regulators activated in cervical cancer.

Authors:  Beiwei Yu; Long Chen; Weina Zhang; Yue Li; Yibiao Zhang; Yuan Gao; Xianlin Teng; Libo Zou; Qian Wang; Hongtao Jia; Xiangtao Liu; Hui Zheng; Ping Hou; Hongyan Yu; Ying Sun; Zhiqin Zhang; Ping Zhang; Liqin Zhang
Journal:  BMC Med Genomics       Date:  2020-10-06       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.